A型肉毒毒素局部注射治疗结缔组织病相关雷诺现象的疗效观察

Abstract
Figure/Table
References
Related Citation (0)

Download: PDF (2777 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical efficacy and safety of botulinum neurotoxin type A (BTX-A) local injection in the treatment of Raynaud's phenomenon (RP) associated with connective tissue disease. Methods Subjects with no difference in baseline data of both hands were included. Subjects were randomly selected to inject BTX-A in the area of bifurcation of neurovascular bundle around fingers with one hand as the injection side and the other hand as the control side. Visual analogue pain scale (VAS) scores, Raynaud's score (RS) and ulcer score (RS) were recorded at 0, 2, 8 and 12 weeks score, US), average fingertip skin temperature, average capillary filling time and occurrence of adverse reactions were statistically analyzed by SPSS 25.0 software. Results 27 patients completed treatment and follow-up. After 2, 8, and 12 weeks of treatment, there was a statistical difference in the overall mean VAS score between the injection side and the control side. After 8, 12 weeks of treatment, there was a statistically significant difference in the mean Reynolds score between the injection side and the control side. There were no significant differences in Reynolds score at 2 weeks, ulcer score at 2, 8 and 12 weeks, average fingerend skin temperature and average percutaneous oxygen saturation. VAS scores at 2, 8 and 12 weeks of treatment were statistically significant compared with those before treatment, Raynaud scores at 8 and 12 weeks of treatment were statistically significant compared with those before treatment, ulcer scores at 8 and 12 weeks of treatment were statistically significant compared with those before treatment, there was no significant difference in the remaining observation indicators before and after treatment. Conclusion Local injection of botulinum toxin type A can improve the pain of patients with Raynaud, reduce the frequency of Raynaud phenomenon, promote ulcer healing with less adverse reactions, and is a safe, effective, simple and feasible method.

Key words： botulinum toxin A connective tissue disease Reynaud's phenomenon finger ischemia finger ischemic ulcer

Received: 30 August 2023

PACS:

R593.2

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIU Xinglin
	ZHANG Hao
	WEI Cui'e
	LI Ming

Cite this article:

LIU Xinglin,ZHANG Hao,WEI Cui'e等. Botulinum toxin A in the local injection treatment of Raynaud phenomenon in connective tissue disease and efficacy observation[J]. HuNan ShiFan DaXue XueBao(YiXueBan), 2024, 21(2): 56-60.

URL:

http://yxb.hunnu.edu.cn/EN/ OR http://yxb.hunnu.edu.cn/EN/Y2024/V21/I2/56

[1] 罗靓, 蔡青猛, 刘香君, 等. 以雷诺现象为首发表现的系统性硬化症临床特征及其相关因素[J]. 北京大学学报 (医学版), 2022, 54(06): 1224-1228.
[2] 姚宏凯, 刘迎, 靳令经. A型肉毒毒素改善雷诺现象血管痉挛的作用及机制研究进展[J]. 国际神经病学神经外科学杂志, 2020, 47(06): 641-644.
[3] 吴丹, 荣晓凤. 雷诺综合征的中西医诊治研究进展[J]. 现代中西医结合杂志, 2021, 30(30): 3415-3420.
[4] 戴翔, 刘彦国, 王俊. 胸腔镜下交感神经切断术治疗雷诺综合征新进展[J]. 中华胸心血管外科杂志, 2018, 34(9): 565-567.
[5] 王远卓, 郑清月, 张翰林, 等. A型肉毒毒素治疗雷诺现象的研究进展[J]. 基础医学与临床, 2022, 42(10): 1611-1615.
[6] WINTER AR, CAMARGO MACIAS K, KIM S, et al.The Effect of Abobotulinum Toxin A on the Symptoms of Raynaud＇s Phenomenon: A Case Series[J]. Cureus, 2020, 12(5): 8235.
[7] HABIB SM, BRENNINKMEIJER EEA, VERMEER MH, et al.Botulinum toxin type A in the treatment of Raynaud's phenomenon[J]. Dermatol Ther, 2020, 33(6): e14182.
[8] QUINTANA CASTANEDO L, FEITO RODRÍGUEZ M, MASEDA PEDRERO R, et al. Ischemic ulcers of the toes secondary to Raynaud's phenomenon in a child successfully treated with botulinum toxin[J]. Pediatr Dermatol, 2020, 37(4): 681-683.
[9] DHALIWAL K, GRIFFIN MF, SALINAS S, et al.Optimisation of botulinum toxin type a treatment for the management of Raynaud's phenomenon using a dorsal approach: a prospective case series[J]. Clin Rheumatol, 2019, 38(12): 3669-3676.
[10] MEDINA S, GÓMEZ-ZUBIAUR A, VALDEOLIVAS-CASILLAS N, et al. Botulinum toxin type A in the treatment of Raynaud＇s phenomenon: A three-year follow-up study[J]. Eur J Rheumatol, 2018, 5(4): 224-229.
[11] NAGARAJAN M, MCARTHUR P.Targeted high concentration botulinum toxin A injections in patients with Raynaud's phenomenon: a retrospective single-centre experience[J]. Rheumatol Int, 2021, 41(5): 943-949.
[12] MERKEL P A, HERLYN K, MARTIN R W, et al.Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon[J]. Arthritis Rheum, 2002, 46(9): 2410-2420.
[13] 周末. A型肉毒毒素治疗系统性硬化症继发雷诺现象的疗效及皮肤镜评估[D]. 北京协和医学院, 2017.
[14] SEYEDMARDANI SM, AGHDASHI MA, SOLTANI S, et al. Evaluation of Botulinum Toxin Type A and its Potential Effect on Exacerbated Raynaud's Phenomenon in Hospitalized Scleroderma Patients[J]. Curr Rheumatol Rev, 2022, 18, (1): 48-57.
[15] GOLDBERG SH, AKOON A, KIRCHNER HL, et al. The Effects of Botulinum Toxin A on Pain in Ischemic Vasospasm[J]. J Hand Surg Am, 2021, 46(6): 513. e1-513. e12.
[16] UPPAL L, DHALIWAL K, BUTLER PE.A prospective study of the use of botulinum toxin injections in the treatment of Raynaud's syndrome associated with scleroderma[J]. J Hand Surg Eur Vol, 2014, 39(8): 876-880.
[17] JOKAR MH, BAGHBANI B, GERAYLOW KR, et al.Efficacy of botulinum toxin type A injection for Raynaud's phenomenon and digital ulcers in patients with systemic sclerosis[J]. Reumatologia, 2022, 60(6): 392-398.
[18] SENET P, MAILLARD H, DIOT E, et al.Efficacy and Safety of Botulinum Toxin in Adults with Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study[J]. Arthritis Rheumatol, 2023, 75(3): 459-467.
[19] BELLO RJ, COONEY CM, MELAMED E, et al.The Therapeutic Efficacy of Botulinum Toxin in Treating Scleroderma-Associated Raynaud's Phenomenon: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial[J]. Arthritis Rheumatol, 2017, 69(8): 1661-1669.
[20] JENKINS SN, NEYMAN KM, VELEDAR E, et al.A pilot study evaluating the efficacy of botulinum toxin A in the treatment of Raynaud phenomenon[J]. J Am Acad Dermatol, 2013, 69(5): 834-835.